StockMacro
Menu

IQVIA

$245.82 +52% in 6 monthsMarket cap $40.5B

IQV on XNYS, Health Care, IQVIA Holdings Inc., job postings

Measures activity, not value. Not investment advice.

Shares fell 11% in a month, though 209 institutions opened new positions, 1.7 times a year earlier.

  • GoodQuarterly revenue up 8.0% to $4.4B, with twelve-month net income up 8.7%

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.

Industry
Services-commercial physical & biological research (Health Care)
Employees
95,000
Website
iqvia.com
Listed
NYSE, US
Last results
27 Oct 2026
Next results
expected around 4 Feb 2027 (an estimate: a year ago it reported on 5 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $4.4B, net income $350.0M.
Quarter to 31 Dec 2021: revenue $3.6B, net income $318.0MQuarter to 31 Dec 2021: revenue $3.6B, net income $318.0MQuarter to 31 Mar 2022: revenue $3.6B, net income $325.0MQuarter to 31 Mar 2022: revenue $3.6B, net income $325.0MQuarter to 30 Jun 2022: revenue $3.5B, net income $256.0MQuarter to 30 Jun 2022: revenue $3.5B, net income $256.0MQuarter to 30 Sep 2022: revenue $3.6B, net income $283.0MQuarter to 30 Sep 2022: revenue $3.6B, net income $283.0MQuarter to 31 Dec 2022: revenue $3.7B, net income $227.0MQuarter to 31 Dec 2022: revenue $3.7B, net income $227.0MQuarter to 31 Mar 2023: revenue $3.7B, net income $289.0MQuarter to 31 Mar 2023: revenue $3.7B, net income $289.0MQuarter to 30 Jun 2023: revenue $3.7B, net income $297.0MQuarter to 30 Jun 2023: revenue $3.7B, net income $297.0MQuarter to 30 Sep 2023: revenue $3.7B, net income $303.0MQuarter to 30 Sep 2023: revenue $3.7B, net income $303.0MQuarter to 31 Dec 2023: revenue $3.9B, net income $469.0MQuarter to 31 Dec 2023: revenue $3.9B, net income $469.0MQuarter to 31 Mar 2024: revenue $3.7B, net income $288.0MQuarter to 31 Mar 2024: revenue $3.7B, net income $288.0MQuarter to 30 Jun 2024: revenue $3.8B, net income $363.0MQuarter to 30 Jun 2024: revenue $3.8B, net income $363.0MQuarter to 30 Sep 2024: revenue $3.9B, net income $285.0MQuarter to 30 Sep 2024: revenue $3.9B, net income $285.0MQuarter to 31 Dec 2024: revenue $4.0B, net income $437.0MQuarter to 31 Dec 2024: revenue $4.0B, net income $437.0MQuarter to 31 Mar 2025: revenue $3.8B, net income $249.0MQuarter to 31 Mar 2025: revenue $3.8B, net income $249.0MQuarter to 30 Jun 2025: revenue $4.0B, net income $266.0MQuarter to 30 Jun 2025: revenue $4.0B, net income $266.0MQuarter to 30 Sep 2025: revenue $4.1B, net income $331.0MQuarter to 30 Sep 2025: revenue $4.1B, net income $331.0MQuarter to 31 Dec 2025: revenue $4.4B, net income $514.0MQuarter to 31 Dec 2025: revenue $4.4B, net income $514.0MQuarter to 31 Mar 2026: revenue $4.2B, net income $274.0MQuarter to 31 Mar 2026: revenue $4.2B, net income $274.0MQuarter to 30 Jun 2026: revenue $4.4B, net income $256.0MQuarter to 30 Jun 2026: revenue $4.4B, net income $256.0MQuarter to 30 Sep 2026: revenue $4.4B, net income $350.0MQuarter to 30 Sep 2026: revenue $4.4B, net income $350.0M
31 Dec 2021RevenueNet incometallest bar $4.4B30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$4.4B$350.0M
30 Jun 2026$4.4B$256.0M
31 Mar 2026$4.2B$274.0M
31 Dec 2025$4.4B$514.0M
30 Sep 2025$4.1B$331.0M
30 Jun 2025$4.0B$266.0M
31 Mar 2025$3.8B$249.0M
31 Dec 2024$4.0B$437.0M
30 Sep 2024$3.9B$285.0M
30 Jun 2024$3.8B$363.0M
31 Mar 2024$3.7B$288.0M
31 Dec 2023$3.9B$469.0M
30 Sep 2023$3.7B$303.0M
30 Jun 2023$3.7B$297.0M
31 Mar 2023$3.7B$289.0M
31 Dec 2022$3.7B$227.0M
30 Sep 2022$3.6B$283.0M
30 Jun 2022$3.5B$256.0M
31 Mar 2022$3.6B$325.0M
31 Dec 2021$3.6B$318.0M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $17.3B $15.9B
Revenue growthRevenue of the last 12 months compared with the 12 months before. +8.8% +3.4%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $1.4B $1.3B
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $8.22 $7.28
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 63.5%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 12.8% 13.7% 4.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 8.1% 8.1% 1.0%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 21.7% -16.5%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $2.1B $2.2B
CashCash, cash equivalents and short-term investments on the latest balance sheet. $2.4B $2.0B
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $16.1B $15.0B
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). $13.6B $13.0B
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 2.4 0.00
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $40.41
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 29.1 57.9
P/SPrice to sales: market cap divided by revenue of the last 12 months. 2.3 4.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 3.1 4.4
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 6.1 4.4

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
IQVIAIQV (this company) $40.5B29.12.3+8.8%8.1%
Incyte GenomicsINCY $23.4B57.93.9+25%6.7%
MedpaceMEDP $17.1B33.06.0+20%18.2%
Charles River Laboratories InternationalCRL $15.1B3753.8-1.2%1.0%
NateraNTRA $39.6Bloss13.6+37%-5.7%
BiogenBIIB $36.9B1063.6+2.3%3.4%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$1.9M

bought $0, sold $1.9M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+13%

1,207 13F filers vs 1,064

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

93%

153.0M shares held by 13F filers (30 Sep 2026) of 164.8M outstanding (20 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

1.8%

3.0M shares sold short (30 Oct 2026) of 164.8M outstanding (20 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

2.1

3.0M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+1.7%

3.0M shares sold short in the report before, 3.0M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

28%

28% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 49%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

95K

reported for the year to 30 Sep 2026; +4.4% on the year before (91K)

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+8.0%

$4.4B vs $4.1B (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

+16%

$158.0M vs $136.0M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$540K

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

16

16 articles in the last 7 days; its usual week has 6 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

2.7×

16 articles in the last 7 days; its usual week has 6.

Unusual now sharp changes in the last 90 days, compared with its own past

  • New institutional positions 209, 1.7× a year earlier

Price $245.82 on 20 Nov 2026, +13% over 12 months (12-month range $156.66 to $279.36)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $39.3M in the last 12 months (the 12 months before: -$14.3M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 53 published in the last 12 months (none in the 12 months before).
Revenue per quarter. Revenue $4.4B in the latest quarter, +8.0% on a year earlier.
Capital spending per quarter. Capital spending $158.0M in the latest quarter, +16% on a year earlier.
Institutional holders (13F filers). 1,207 13F filers reported holding it in the latest 13F quarter, +26% on a year earlier.
Lobbying spend. Lobbying spend: $540K published in the last 12 months, -17% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
17 Nov 2026Sharp changeMany funds opening a new position: many funds opening a new position, 209 vs usual 97.50 (2026-09-30); 1.7x the same period a year earlier
20 Jul 2026Sharp changeLobbying on a new issue: lobbying on a new issue: LBR (2026-06-30)
23 Apr 20268-K and other filingsDirector or officer change
23 Apr 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
17 Feb 2026Sharp changeMany funds opening a new position: many funds opening a new position, 159 vs usual 87 (2025-12-31); 2.5x the same period a year earlier
6 Jan 2026Lobbying filinglobbying engagement terminated (HORIZON GOVERNMENT AFFAIRS)
18 Nov 2025Sharp changeMany funds opening a new position: many funds opening a new position, 124 vs usual 84 (2025-09-30); 1.4x the same period a year earlier
5 Nov 20258-K and other filingsDirector or officer change
16 Sep 2025Sharp changeShort interest spike: short interest spike, 4.9M vs usual 3.1M (2025-08-29); 1.8x the same period a year earlier
2 Sep 2025Sharp changeShort interest spike: short interest spike, 5.7M vs usual 3.1M (2025-08-15); 1.7x the same period a year earlier
2 Sep 20258-K and other filingsDirector or officer change
2 Sep 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
12 Aug 2025Sharp changeShort interest spike: short interest spike, 6.8M vs usual 3.1M (2025-07-31); 2.3x the same period a year earlier
29 Jul 2025Sharp changeShort interest spike: short interest spike, 9.0M vs usual 3.1M (2025-07-15); 3.4x the same period a year earlier
1 Jul 2025Sharp changeShort interest spike: short interest spike, 9.3M vs usual 3.1M (2025-06-13); 2.9x the same period a year earlier
17 Jun 2025Sharp changeShort interest spike: short interest spike, 7.2M vs usual 3.1M (2025-05-30); 2.2x the same period a year earlier
3 Jun 2025Sharp changeShort interest spike: short interest spike, 5.6M vs usual 3.1M (2025-05-15); 1.8x the same period a year earlier
10 May 20248-K and other filingsDirector or officer change
10 May 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
31 Oct 2023Sharp changeShort interest spike: short interest spike, 3.9M vs usual 2.0M (2023-10-13); 2.0x the same period a year earlier
17 Oct 2023Sharp changeShort interest spike: short interest spike, 3.5M vs usual 2.0M (2023-09-29); 1.6x the same period a year earlier
3 Oct 2023Sharp changeShort interest spike: short interest spike, 3.5M vs usual 2.0M (2023-09-15); 1.4x the same period a year earlier
26 Sep 20238-K and other filingsDirector or officer change
26 Sep 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
24 Jan 2023Sharp changeLobbying spend jump: lobbying spend jump, 200K vs usual 75K (2022-12-31); 2.2x the same period a year earlier
25 Oct 2022Sharp changeLobbying spend jump: lobbying spend jump, 200K vs usual 60K (2022-09-30); 3.3x the same period a year earlier
3 Oct 20228-K and other filingsDirector or officer change
29 Jul 20228-K and other filingsDirector or officer change
29 Jul 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
26 Jul 2022Sharp changeLobbying spend jump: lobbying spend jump, 200K vs usual 60K (2022-06-30); 3.3x the same period a year earlier
4 Apr 2022Lobbying filingnew lobbying registration (HORIZON GOVERNMENT AFFAIRS)
14 Mar 20228-K and other filingsDirector or officer change
3 Mar 2022Lobbying filingnew lobbying registration (DLA PIPER LLP (US))
26 Jan 20228-K and other filingsDirector or officer change
26 Jan 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
20 Jan 2022Sharp changeLobbying on a new issue: lobbying on a new issue: BUD, SCI (2021-12-31)
14 Jan 2022Lobbying filingnew lobbying registration (ATLAS CROSSING LLC)
Insider net buying (open market)
Month from 1 Dec 2021: -$143.0M published
Month from 1 Feb 2022: $3K published
Month from 1 Feb 2023: -$1.2M published
Month from 1 Jun 2023: -$1.2M published
Month from 1 Sep 2023: -$5.7M published
Month from 1 Dec 2023: -$2.8M published
Month from 1 Feb 2024: -$3.5M published
Month from 1 Mar 2024: -$13.6M published
Month from 1 Aug 2024: -$320K published
Month from 1 Feb 2025: $256K published
Month from 1 Jul 2025: -$1.2M published
Month from 1 Nov 2025: -$13.3M published
Month from 1 Dec 2025: -$8.1M published
Month from 1 Aug 2026: -$29.2M published
Month from 1 Sep 2026: -$697K published
Month from 1 Nov 2026: -$1.2M published
H-1B/E-3 applications certified
Quarter from 1 Oct 2026: 53 published
Revenue per quarter
Quarter ended 31 Dec 2021: $3.6B, +10% on a year earlier; public on 17 Feb 2022
Quarter ended 31 Mar 2022: $3.6B, +4.7% on a year earlier; public on 29 Apr 2022
Quarter ended 30 Jun 2022: $3.5B, +3.0% on a year earlier; public on 23 Jul 2022
Quarter ended 30 Sep 2022: $3.6B, +5.0% on a year earlier; public on 28 Oct 2022
Quarter ended 31 Dec 2022: $3.7B, +2.8% on a year earlier; public on 16 Feb 2023
Quarter ended 31 Mar 2023: $3.7B, +2.4% on a year earlier; public on 29 Apr 2023
Quarter ended 30 Jun 2023: $3.7B, +5.3% on a year earlier; public on 2 Aug 2023
Quarter ended 30 Sep 2023: $3.7B, +4.9% on a year earlier; public on 2 Nov 2023
Quarter ended 31 Dec 2023: $3.9B, +3.5% on a year earlier; public on 16 Feb 2024
Quarter ended 31 Mar 2024: $3.7B, +2.3% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $3.8B, +2.3% on a year earlier; public on 23 Jul 2024
Quarter ended 30 Sep 2024: $3.9B, +4.3% on a year earlier; public on 1 Nov 2024
Quarter ended 31 Dec 2024: $4.0B, +2.3% on a year earlier; public on 14 Feb 2025
Quarter ended 31 Mar 2025: $3.8B, +2.5% on a year earlier; public on 7 May 2025
Quarter ended 30 Jun 2025: $4.0B, +5.3% on a year earlier; public on 23 Jul 2025
Quarter ended 30 Sep 2025: $4.1B, +5.2% on a year earlier; public on 29 Oct 2025
Quarter ended 31 Dec 2025: $4.4B, +10% on a year earlier; public on 18 Feb 2026
Quarter ended 31 Mar 2026: $4.2B, +8.4% on a year earlier; public on 6 May 2026
Quarter ended 30 Jun 2026: $4.4B, +8.7% on a year earlier; public on 29 Jul 2026
Quarter ended 30 Sep 2026: $4.4B, +8.0% on a year earlier; public on 28 Oct 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $184.0M, +4.5% on a year earlier; public on 17 Feb 2022
Quarter ended 31 Mar 2022: $177.0M, +19% on a year earlier; public on 29 Apr 2022
Quarter ended 30 Jun 2022: $161.0M, +11% on a year earlier; public on 23 Jul 2022
Quarter ended 30 Sep 2022: $165.0M, +1.9% on a year earlier; public on 28 Oct 2022
Quarter ended 31 Dec 2022: $171.0M, -7.1% on a year earlier; public on 16 Feb 2023
Quarter ended 31 Mar 2023: $164.0M, -7.3% on a year earlier; public on 29 Apr 2023
Quarter ended 30 Jun 2023: $160.0M, -0.6% on a year earlier; public on 2 Aug 2023
Quarter ended 30 Sep 2023: $146.0M, -12% on a year earlier; public on 2 Nov 2023
Quarter ended 31 Dec 2023: $179.0M, +4.7% on a year earlier; public on 16 Feb 2024
Quarter ended 31 Mar 2024: $145.0M, -12% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $143.0M, -11% on a year earlier; public on 23 Jul 2024
Quarter ended 30 Sep 2024: $150.0M, +2.7% on a year earlier; public on 1 Nov 2024
Quarter ended 31 Dec 2024: $164.0M, -8.4% on a year earlier; public on 14 Feb 2025
Quarter ended 31 Mar 2025: $142.0M, -2.1% on a year earlier; public on 7 May 2025
Quarter ended 30 Jun 2025: $151.0M, +5.6% on a year earlier; public on 23 Jul 2025
Quarter ended 30 Sep 2025: $136.0M, -9.3% on a year earlier; public on 29 Oct 2025
Quarter ended 31 Dec 2025: $174.0M, +6.1% on a year earlier; public on 18 Feb 2026
Quarter ended 31 Mar 2026: $127.0M, -11% on a year earlier; public on 6 May 2026
Quarter ended 30 Jun 2026: $198.0M, +31% on a year earlier; public on 29 Jul 2026
Quarter ended 30 Sep 2026: $158.0M, +16% on a year earlier; public on 28 Oct 2026
Institutional holders (13F filers)
31 Dec 2021 report: 823; public on 14 Feb 2022
31 Mar 2022 report: 843; public on 16 May 2022
30 Jun 2022 report: 827; public on 15 Aug 2022
30 Sep 2022 report: 801; public on 14 Nov 2022
31 Dec 2022 report: 837; public on 14 Feb 2023
31 Mar 2023 report: 851; public on 15 May 2023
30 Jun 2023 report: 846; public on 14 Aug 2023
30 Sep 2023 report: 865; public on 14 Nov 2023
31 Dec 2023 report: 883; public on 14 Feb 2024
31 Mar 2024 report: 957; public on 15 May 2024
30 Jun 2024 report: 962; public on 14 Aug 2024
30 Sep 2024 report: 992; public on 14 Nov 2024
31 Dec 2024 report: 951; public on 14 Feb 2025
31 Mar 2025 report: 945; public on 15 May 2025
30 Jun 2025 report: 935; public on 14 Aug 2025
30 Sep 2025 report: 958; public on 14 Nov 2025
31 Dec 2025 report: 1,089; public on 17 Feb 2026
31 Mar 2026 report: 1,042; public on 15 May 2026
30 Jun 2026 report: 1,064; public on 14 Aug 2026
30 Sep 2026 report: 1,207; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $90K published
Quarter from 1 Apr 2022: $150K published
Quarter from 1 Jul 2022: $200K published
Quarter from 1 Oct 2022: $200K published
Quarter from 1 Jan 2023: $200K published
Quarter from 1 Apr 2023: $170K published
Quarter from 1 Jul 2023: $170K published
Quarter from 1 Oct 2023: $170K published
Quarter from 1 Jan 2024: $180K published
Quarter from 1 Apr 2024: $170K published
Quarter from 1 Jul 2024: $170K published
Quarter from 1 Oct 2024: $170K published
Quarter from 1 Jan 2025: $170K published
Quarter from 1 Apr 2025: $210K published
Quarter from 1 Jul 2025: $150K published
Quarter from 1 Oct 2025: $120K published
Quarter from 1 Jan 2026: $120K published
Quarter from 1 Apr 2026: $120K published
Quarter from 1 Jul 2026: $120K published
Quarter from 1 Oct 2026: $180K published

What is unusual now

  • Made public in the last 90 days: it saw 209 13F filers open a new position in the quarter ended 30 Sep 2026, 1.7× the same quarter last year.
  • Many funds opening a new position: saw 209 13F filers open a new position in the quarter ended 30 Sep 2026, 1.7× the same quarter last year Public on 16 Nov 2026.
  • Lobbying on a new issue: lobbying on a new issue Public on 20 Jul 2026.
  • Insider net buying (open market): Insiders sold a net $39.3M in the last 12 months (the 12 months before: -$14.3M).

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 2 sales, $1.9M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
12 Nov 2026Eric SherbetSee RemarksSellafter exercising options4,446$278.83$1.2MForm 4
4 Sep 2026James G. BerkshireSee RemarksSellafter exercising options2,668$261.33$697KForm 4
4 Aug 2026W Richard StaubSee RemarksSell5,500$232.68$1.3MForm 4
4 Aug 2026Bhavik PatelSee RemarksSell1,855$235.27$436KForm 4
31 Jul 2026Ari BousbibSee RemarksSellafter exercising options106,279$245.51$26.1MForm 4
31 Jul 2026Keriann CherofskySee RemarksSell558$245.21$137KForm 4
31 Jul 2026Eric SherbetSee RemarksSell5,000$249.16$1.2MForm 4
19 Dec 2025Ari BousbibSee RemarksSellafter exercising options36,564$222.43$8.1MForm 4

1,207 institutions reported shares at the end of Q3 2026, 93% of the shares outstanding; 207 opened a position, 74 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.14.4M8.76%$3.9B-116K-0.8%
Vanguard Capital Management LLC10.8M6.54%$2.9B-128K-1.2%
Harris Associates L P10.4M6.34%$2.8B-1.7M-14%
State Street Corp7.5M4.56%$2.0B+8,254+0.1%
Vanguard Portfolio Management LLC7.4M4.47%$2.0B-140K-1.9%
Geode Capital Management, LLC4.4M2.69%$1.2B-29K-0.6%
Boston Partners4.4M2.65%$1.2B-97K-2.2%
JPMorgan Chase & Co4.3M2.62%$1.2B-1.8M-30%
Artisan Partners Limited Partnership3.5M2.10%$930.6M-1.3M-27%
Invesco Ltd.2.9M1.79%$791.3M-332K-10%

Company events

All 55 company events

In 12 months: 3 major agreements, 1 director or officer change. Results releases and routine reports are left out.

FiledWhat happenedSource
23 Sep 2026Signed a major agreementSame filing: took on new debt8-K
11 Jun 2026Signed a major agreementSame filing: took on new debt8-K
23 Apr 2026Director or officer changeSame filing: shareholder vote results8-K
9 Dec 2025Signed a major agreementSame filing: took on new debt8-K
5 Nov 2025Director or officer change8-K
2 Sep 2025Director or officer change8-K
4 Jun 2025Signed a major agreementSame filing: took on new debt8-K
10 Mar 2025Signed a major agreementSame filing: took on new debt8-K

Reported lobbying spend: $180K in Q3 2026, $120K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
31 Dec 2025EndedHorizon Government Affairsfor IqviaNot statedFiling
1 Mar 2022NewHorizon Government Affairsfor Iqviaclinical trials, drug pricingHealth issuesFiling
13 Jan 2022NewDla Piper LLP (US)for Iqvia Holdings, Inc.Federal market support for data-driven products and services.Health issuesFiling
1 Dec 2021NewAtlas Crossing LLCfor IqviaMonitor COVID relief issues. Appropriations.Budget, Science/technologyFiling
31 Dec 2020EndedWashington Health Strategies Groupfor Quintiles Transnational Corporationclinical researchHealth issuesFiling
1 Jan 2019NewRepublic Consulting, LLCfor IqviaMonitor Data and Science policyHealth issues, Pharmacy, MEDFiling
31 Dec 2018EndedWexler | Walker, A Unit Of Hill+Knowlton Strategies, LLCfor Iqvia (Formerly Quintilesims And Ims Health Inc)Health Information Technology Medical Records Privacy Health Information Transparency Data Use Policy Clinical Research PolicyHealth issuesFiling
1 Jan 2009NewWashington Health Strategies Groupfor Quintiles Transnational CorporationMedical Records Privacy Conduct of clinical trials drug safety public health preparednessHealth issuesFiling

The 5 newest of 340 articles that name the company.

Timeline

Timeline

Changes and notable records, by the date each became public

  1. 16 Nov 2026Institutional holdings change

    saw 209 13F filers open a new position in the quarter ended 30 Sep 2026, 1.7× the same quarter last year.

    Same quarter last year: 124; its normal quarter is 97.5.

    See the evidence
    This period
    209 (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    97.5
    Typical spread (median absolute deviation)
    18
    How far from its usual level
    +4.2
    Same quarter last year
    124
    History used
    3,195 days
    2024-09-30: 892024-12-31: 632025-03-31: 852025-06-30: 1042025-09-30: 1242025-12-31: 1592026-03-31: 912026-06-30: 1212026-09-30: 209
    the quarter ended 30 Sep 20268 earlier quartersnormal: 97.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  2. 10 Nov 2026Institutional holdings record

    WCM INVESTMENT MANAGEMENT, LLC opened a $718.0M position (2026Q3 13F)

  3. 20 Jul 2026Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['LBR']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    12771079
  4. 23 Apr 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  5. 23 Apr 2026Filings record

    Director or officer change

  6. 17 Feb 2026Institutional holdings change

    saw 159 13F filers open a new position in the quarter ended 31 Dec 2025, 2.5× the same quarter last year.

    Same quarter last year: 63; its normal quarter is 87.

    See the evidence
    This period
    159 (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    87
    Typical spread (median absolute deviation)
    10.5
    How far from its usual level
    +4.6
    Same quarter last year
    63
    History used
    2,922 days
    2023-12-31: 602024-03-31: 892024-06-30: 832024-09-30: 892024-12-31: 632025-03-31: 852025-06-30: 1042025-09-30: 1242025-12-31: 159
    the quarter ended 31 Dec 20258 earlier quartersnormal: 87

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  7. 6 Jan 2026Lobbying record

    IQVIA: lobbying engagement terminated (HORIZON GOVERNMENT AFFAIRS) (dated 31 Dec 2025)

  8. 14 Nov 2025Institutional holdings change

    saw 124 13F filers open a new position in the quarter ended 30 Sep 2025, 1.4× the same quarter last year.

    Same quarter last year: 89; its normal quarter is 84.

    See the evidence
    This period
    124 (the quarter ended 30 Sep 2025)
    Normal quarter (median of 8 earlier)
    84
    Typical spread (median absolute deviation)
    7.5
    How far from its usual level
    +3.6
    Same quarter last year
    89
    History used
    2,830 days
    2023-09-30: 742023-12-31: 602024-03-31: 892024-06-30: 832024-09-30: 892024-12-31: 632025-03-31: 852025-06-30: 1042025-09-30: 124
    the quarter ended 30 Sep 20258 earlier quartersnormal: 84

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  9. 13 Nov 2025Institutional holdings record

    Boston Partners opened a $677.0M position (2025Q3 13F)

  10. 5 Nov 2025Filings record

    Director or officer change

  11. 11 Sep 2025Short interest and volume change

    had 4.9M shares sold short in the 29 Aug 2025 report, 1.8× the same report last year.

    Same report last year: 2.8M; its normal report is 3.1M.

    See the evidence
    This period
    4.9M (the 29 Aug 2025 report)
    Normal report (median of 24 earlier)
    3.1M
    Typical spread (median absolute deviation)
    329K
    How far from its usual level
    +3.7
    Same report last year
    2.8M
    History used
    2,800 days
    2024-08-30: 2.8M2024-09-13: 3.2M2024-09-30: 3.1M2024-10-15: 2.9M2024-10-31: 2.6M2024-11-15: 3.3M2024-11-29: 3.1M2024-12-13: 2.8M2024-12-31: 3.1M2025-01-15: 3.0M2025-01-31: 2.9M2025-02-14: 2.8M2025-02-28: 3.5M2025-03-14: 3.8M2025-03-31: 3.2M2025-04-15: 2.9M2025-04-30: 2.8M2025-05-15: 5.6M2025-05-30: 7.2M2025-06-13: 9.3M2025-06-30: 9.1M2025-07-15: 9.0M2025-07-31: 6.8M2025-08-15: 5.7M2025-08-29: 4.9M
    the 29 Aug 2025 report24 earlier reportsnormal: 3.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  12. 2 Sep 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  13. 2 Sep 2025Filings record

    Director or officer change

  14. 27 Aug 2025Short interest and volume change

    had 5.7M shares sold short in the 15 Aug 2025 report, 1.7× the same report last year.

    Same report last year: 3.3M; its normal report is 3.1M.

    See the evidence
    This period
    5.7M (the 15 Aug 2025 report)
    Normal report (median of 24 earlier)
    3.1M
    Typical spread (median absolute deviation)
    322K
    How far from its usual level
    +5.4
    Same report last year
    3.3M
    History used
    2,786 days
    2024-08-15: 3.3M2024-08-30: 2.8M2024-09-13: 3.2M2024-09-30: 3.1M2024-10-15: 2.9M2024-10-31: 2.6M2024-11-15: 3.3M2024-11-29: 3.1M2024-12-13: 2.8M2024-12-31: 3.1M2025-01-15: 3.0M2025-01-31: 2.9M2025-02-14: 2.8M2025-02-28: 3.5M2025-03-14: 3.8M2025-03-31: 3.2M2025-04-15: 2.9M2025-04-30: 2.8M2025-05-15: 5.6M2025-05-30: 7.2M2025-06-13: 9.3M2025-06-30: 9.1M2025-07-15: 9.0M2025-07-31: 6.8M2025-08-15: 5.7M
    the 15 Aug 2025 report24 earlier reportsnormal: 3.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  15. 12 Aug 2025Short interest and volume change

    had 6.8M shares sold short in the 31 Jul 2025 report, 2.3× the same report last year.

    Same report last year: 2.9M; its normal report is 3.1M.

    See the evidence
    This period
    6.8M (the 31 Jul 2025 report)
    Normal report (median of 24 earlier)
    3.1M
    Typical spread (median absolute deviation)
    264K
    How far from its usual level
    +9.4
    Same report last year
    2.9M
    History used
    2,771 days
    2024-07-31: 2.9M2024-08-15: 3.3M2024-08-30: 2.8M2024-09-13: 3.2M2024-09-30: 3.1M2024-10-15: 2.9M2024-10-31: 2.6M2024-11-15: 3.3M2024-11-29: 3.1M2024-12-13: 2.8M2024-12-31: 3.1M2025-01-15: 3.0M2025-01-31: 2.9M2025-02-14: 2.8M2025-02-28: 3.5M2025-03-14: 3.8M2025-03-31: 3.2M2025-04-15: 2.9M2025-04-30: 2.8M2025-05-15: 5.6M2025-05-30: 7.2M2025-06-13: 9.3M2025-06-30: 9.1M2025-07-15: 9.0M2025-07-31: 6.8M
    the 31 Jul 2025 report24 earlier reportsnormal: 3.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  16. 12 Aug 2025Institutional holdings record

    Artisan Partners Limited Partnership opened a $516.0M position (2025Q2 13F)

  17. 25 Jul 2025Short interest and volume change

    had 9.0M shares sold short in the 15 Jul 2025 report, 3.4× the same report last year.

    Same report last year: 2.7M; its normal report is 3.1M.

    See the evidence
    This period
    9.0M (the 15 Jul 2025 report)
    Normal report (median of 24 earlier)
    3.1M
    Typical spread (median absolute deviation)
    264K
    How far from its usual level
    +15.2
    Same report last year
    2.7M
    History used
    2,755 days
    2024-07-15: 2.7M2024-07-31: 2.9M2024-08-15: 3.3M2024-08-30: 2.8M2024-09-13: 3.2M2024-09-30: 3.1M2024-10-15: 2.9M2024-10-31: 2.6M2024-11-15: 3.3M2024-11-29: 3.1M2024-12-13: 2.8M2024-12-31: 3.1M2025-01-15: 3.0M2025-01-31: 2.9M2025-02-14: 2.8M2025-02-28: 3.5M2025-03-14: 3.8M2025-03-31: 3.2M2025-04-15: 2.9M2025-04-30: 2.8M2025-05-15: 5.6M2025-05-30: 7.2M2025-06-13: 9.3M2025-06-30: 9.1M2025-07-15: 9.0M
    the 15 Jul 2025 report24 earlier reportsnormal: 3.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  18. 26 Jun 2025Short interest and volume change

    had 9.3M shares sold short in the 13 Jun 2025 report, 2.9× the same report last year.

    Same report last year: 3.2M; its normal report is 3.1M.

    See the evidence
    This period
    9.3M (the 13 Jun 2025 report)
    Normal report (median of 24 earlier)
    3.1M
    Typical spread (median absolute deviation)
    197K
    How far from its usual level
    +20.2
    Same report last year
    3.2M
    History used
    2,723 days
    2024-06-14: 3.2M2024-06-28: 3.1M2024-07-15: 2.7M2024-07-31: 2.9M2024-08-15: 3.3M2024-08-30: 2.8M2024-09-13: 3.2M2024-09-30: 3.1M2024-10-15: 2.9M2024-10-31: 2.6M2024-11-15: 3.3M2024-11-29: 3.1M2024-12-13: 2.8M2024-12-31: 3.1M2025-01-15: 3.0M2025-01-31: 2.9M2025-02-14: 2.8M2025-02-28: 3.5M2025-03-14: 3.8M2025-03-31: 3.2M2025-04-15: 2.9M2025-04-30: 2.8M2025-05-15: 5.6M2025-05-30: 7.2M2025-06-13: 9.3M
    the 13 Jun 2025 report24 earlier reportsnormal: 3.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  19. 11 Jun 2025Short interest and volume change

    had 7.2M shares sold short in the 30 May 2025 report, 2.2× the same report last year.

    Same report last year: 3.2M; its normal report is 3.1M.

    See the evidence
    This period
    7.2M (the 30 May 2025 report)
    Normal report (median of 24 earlier)
    3.1M
    Typical spread (median absolute deviation)
    180K
    How far from its usual level
    +13.3
    Same report last year
    3.2M
    History used
    2,709 days
    2024-05-31: 3.2M2024-06-14: 3.2M2024-06-28: 3.1M2024-07-15: 2.7M2024-07-31: 2.9M2024-08-15: 3.3M2024-08-30: 2.8M2024-09-13: 3.2M2024-09-30: 3.1M2024-10-15: 2.9M2024-10-31: 2.6M2024-11-15: 3.3M2024-11-29: 3.1M2024-12-13: 2.8M2024-12-31: 3.1M2025-01-15: 3.0M2025-01-31: 2.9M2025-02-14: 2.8M2025-02-28: 3.5M2025-03-14: 3.8M2025-03-31: 3.2M2025-04-15: 2.9M2025-04-30: 2.8M2025-05-15: 5.6M2025-05-30: 7.2M
    the 30 May 2025 report24 earlier reportsnormal: 3.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  20. 28 May 2025Short interest and volume change

    had 5.6M shares sold short in the 15 May 2025 report, 1.8× the same report last year.

    Same report last year: 3.0M; its normal report is 3.1M.

    See the evidence
    This period
    5.6M (the 15 May 2025 report)
    Normal report (median of 24 earlier)
    3.1M
    Typical spread (median absolute deviation)
    162K
    How far from its usual level
    +8.2
    Same report last year
    3.0M
    History used
    2,694 days
    2024-05-15: 3.0M2024-05-31: 3.2M2024-06-14: 3.2M2024-06-28: 3.1M2024-07-15: 2.7M2024-07-31: 2.9M2024-08-15: 3.3M2024-08-30: 2.8M2024-09-13: 3.2M2024-09-30: 3.1M2024-10-15: 2.9M2024-10-31: 2.6M2024-11-15: 3.3M2024-11-29: 3.1M2024-12-13: 2.8M2024-12-31: 3.1M2025-01-15: 3.0M2025-01-31: 2.9M2025-02-14: 2.8M2025-02-28: 3.5M2025-03-14: 3.8M2025-03-31: 3.2M2025-04-15: 2.9M2025-04-30: 2.8M2025-05-15: 5.6M
    the 15 May 2025 report24 earlier reportsnormal: 3.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  21. 8 Feb 2025Insiders record

    DANHAKL JOHN G (director) bought 1,275 shares of IQV ($255,740) (dated 7 Feb 2025)

  22. 10 May 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  23. 10 May 2024Filings record

    Director or officer change

  24. 25 Oct 2023Short interest and volume change

    had 3.9M shares sold short in the 13 Oct 2023 report, 2.0× the same report last year.

    Same report last year: 2.0M; its normal report is 2.0M.

    See the evidence
    This period
    3.9M (the 13 Oct 2023 report)
    Normal report (median of 24 earlier)
    2.0M
    Typical spread (median absolute deviation)
    264K
    How far from its usual level
    +4.9
    Same report last year
    2.0M
    History used
    2,114 days
    2022-10-14: 2.0M2022-10-31: 1.9M2022-11-15: 2.3M2022-11-30: 1.8M2022-12-15: 1.7M2022-12-30: 1.5M2023-01-13: 2.0M2023-01-31: 1.8M2023-02-15: 1.6M2023-02-28: 1.7M2023-03-15: 1.7M2023-03-31: 2.2M2023-04-14: 1.8M2023-04-28: 1.6M2023-05-15: 2.0M2023-05-31: 2.4M2023-06-15: 2.3M2023-06-30: 2.4M2023-07-14: 2.3M2023-07-31: 2.2M2023-08-15: 2.4M2023-08-31: 3.1M2023-09-15: 3.5M2023-09-29: 3.5M2023-10-13: 3.9M
    the 13 Oct 2023 report24 earlier reportsnormal: 2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  25. 12 Oct 2023Short interest and volume change

    had 3.5M shares sold short in the 29 Sep 2023 report, 1.6× the same report last year.

    Same report last year: 2.2M; its normal report is 2.0M.

    See the evidence
    This period
    3.5M (the 29 Sep 2023 report)
    Normal report (median of 24 earlier)
    2.0M
    Typical spread (median absolute deviation)
    261K
    How far from its usual level
    +3.8
    Same report last year
    2.2M
    History used
    2,100 days
    2022-09-30: 2.2M2022-10-14: 2.0M2022-10-31: 1.9M2022-11-15: 2.3M2022-11-30: 1.8M2022-12-15: 1.7M2022-12-30: 1.5M2023-01-13: 2.0M2023-01-31: 1.8M2023-02-15: 1.6M2023-02-28: 1.7M2023-03-15: 1.7M2023-03-31: 2.2M2023-04-14: 1.8M2023-04-28: 1.6M2023-05-15: 2.0M2023-05-31: 2.4M2023-06-15: 2.3M2023-06-30: 2.4M2023-07-14: 2.3M2023-07-31: 2.2M2023-08-15: 2.4M2023-08-31: 3.1M2023-09-15: 3.5M2023-09-29: 3.5M
    the 29 Sep 2023 report24 earlier reportsnormal: 2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  26. 27 Sep 2023Short interest and volume change

    had 3.5M shares sold short in the 15 Sep 2023 report, 1.4× the same report last year.

    Same report last year: 2.5M; its normal report is 2.0M.

    See the evidence
    This period
    3.5M (the 15 Sep 2023 report)
    Normal report (median of 24 earlier)
    2.0M
    Typical spread (median absolute deviation)
    261K
    How far from its usual level
    +4.0
    Same report last year
    2.5M
    History used
    2,086 days
    2022-09-15: 2.5M2022-09-30: 2.2M2022-10-14: 2.0M2022-10-31: 1.9M2022-11-15: 2.3M2022-11-30: 1.8M2022-12-15: 1.7M2022-12-30: 1.5M2023-01-13: 2.0M2023-01-31: 1.8M2023-02-15: 1.6M2023-02-28: 1.7M2023-03-15: 1.7M2023-03-31: 2.2M2023-04-14: 1.8M2023-04-28: 1.6M2023-05-15: 2.0M2023-05-31: 2.4M2023-06-15: 2.3M2023-06-30: 2.4M2023-07-14: 2.3M2023-07-31: 2.2M2023-08-15: 2.4M2023-08-31: 3.1M2023-09-15: 3.5M
    the 15 Sep 2023 report24 earlier reportsnormal: 2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  27. 26 Sep 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  28. 26 Sep 2023Filings record

    Director or officer change

  29. 14 Aug 2023Institutional holdings record

    HARRIS ASSOCIATES L P opened a $359.0M position (2023Q2 13F)

  30. 20 Jan 2023Lobbying change

    reported $200K of lobbying spend for the quarter ended 31 Dec 2022, 2.2× the same quarter last year.

    Same quarter last year: $90K; its normal quarter is $75K.

    See the evidence
    This period
    $200K (the quarter ended 31 Dec 2022)
    Normal quarter (median of 8 earlier)
    $75K
    Typical spread (median absolute deviation)
    $15K
    How far from its usual level
    +5.6
    Same quarter last year
    $90K
    History used
    4,748 days
    2020-12-31: $60K2021-03-31: $60K2021-06-30: $60K2021-09-30: $60K2021-12-31: $90K2022-03-31: $150K2022-06-30: $200K2022-09-30: $200K2022-12-31: $200K
    the quarter ended 31 Dec 20228 earlier quartersnormal: $75K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

    Check it at the source: Senate/House lobbying disclosures (LDA).

  31. 19 Oct 2022Lobbying change

    reported $200K of lobbying spend for the quarter ended 30 Sep 2022, 3.3× the same quarter last year.

    Same quarter last year: $60K; its normal quarter is $60K.

    See the evidence
    This period
    $200K (the quarter ended 30 Sep 2022)
    Normal quarter (median of 8 earlier)
    $60K
    Typical spread (median absolute deviation)
    $0
    How far from its usual level
    +7.0
    Same quarter last year
    $60K
    History used
    4,656 days
    2020-09-30: $60K2020-12-31: $60K2021-03-31: $60K2021-06-30: $60K2021-09-30: $60K2021-12-31: $90K2022-03-31: $150K2022-06-30: $200K2022-09-30: $200K
    the quarter ended 30 Sep 20228 earlier quartersnormal: $60K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

    Check it at the source: Senate/House lobbying disclosures (LDA).

  32. 3 Oct 2022Filings record

    Director or officer change

  33. 29 Jul 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  34. 29 Jul 2022Filings record

    Director or officer change

  35. 20 Jul 2022Lobbying change

    reported $200K of lobbying spend for the quarter ended 30 Jun 2022, 3.3× the same quarter last year.

    Same quarter last year: $60K; its normal quarter is $60K.

    See the evidence
    This period
    $200K (the quarter ended 30 Jun 2022)
    Normal quarter (median of 8 earlier)
    $60K
    Typical spread (median absolute deviation)
    $0
    How far from its usual level
    +7.0
    Same quarter last year
    $60K
    History used
    4,474 days
    2020-06-30: $60K2020-09-30: $60K2020-12-31: $60K2021-03-31: $60K2021-06-30: $60K2021-09-30: $60K2021-12-31: $90K2022-03-31: $150K2022-06-30: $200K
    the quarter ended 30 Jun 20228 earlier quartersnormal: $60K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

    Check it at the source: Senate/House lobbying disclosures (LDA).

  36. 4 Apr 2022Lobbying record

    IQVIA: new lobbying registration (HORIZON GOVERNMENT AFFAIRS) (dated 1 Mar 2022)

  37. 14 Mar 2022Filings record

    Director or officer change

  38. 3 Mar 2022Lobbying record

    IQVIA HOLDINGS, INC.: new lobbying registration (DLA PIPER LLP (US)) (dated 13 Jan 2022)

  39. 18 Feb 2022Insiders record

    Bruehlman Ronald E (See Remarks) bought 4 shares of IQV ($1,051) (dated 17 Feb 2022)

  40. 15 Feb 2022Insiders record

    Bruehlman Ronald E (See Remarks) bought 13 shares of IQV ($3,189) (dated 14 Feb 2022)

Showing the newest 40 of 87 entries; narrow the window or the kind of data to see older ones.

Not listed: 270 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001478242
Ticker
IQV
Domain
iqvia.com
Employer name
iqvia, iqvia digital, iqvia laboratories, IQVIA RDS Inc. and 1 more (4 unverified)
Fein
56-1323952, 56-1755218 (2 unverified)
Hq location
NC|DURHAM|27703 (1 unverified)
Lobbying client
iqvia, iqvia formerly quintilesims and ims health, iqvia holdings, quintiles transnational
Name
159 Solutions, LLC, 159 Technology Solutions Private Ltd, 1HQ Limited, 1HQ (NL) B.V and 411 more
Wikidata
Q305473
Wikipedia
IQVIA
  • DOL H-1B labor condition applications and PERM certifications108 data points5 Jan 2026 to 28 Sep 2026
  • Federal lobbying disclosures (LDA)10 records, 276 data points30 Jun 1999 to 30 Sep 2026
  • SEC Form 13F institutional holdings17 records, 324 data points31 Dec 2017 to 10 Nov 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)167 records11 Feb 2016 to 27 Oct 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)979 data points31 Dec 2010 to 20 Oct 2026
  • SEC Form 4 insider transactions134 records, 408 data points2 Mar 2016 to 12 Nov 2026
  • FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • Wikipedia pageviews2882 data points1 Jan 2019 to 21 Nov 2026